Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-1005 for Ototoxicity in Cystic Fibrosis Patients Receiving IV Tobramycin
NCT02819856Phase 2Completed
- Sponsor
- Sound Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ebselen in ototoxicity, sponsored by Sound Pharmaceuticals. Started Jul 2017; status: completed.
02
Drugs
ebselen
03
Conditions
ototoxicity
Beyond the preview
Go deeper on NCT02819856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819856.